Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Rosetta Genomics Ltd
Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
July 22nd, 2008
Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced that the results of a study conducted by its scientists and collaborators and describing the use of microRNAs in accurately differentiating primary from metastatic tumors of the brain, have been published online in the peer-reviewed journal Brain Pathology. The findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify primary tumors in patients with brain cancers. "This latest study conducted by our scientists, as well as our...
Source: Cancer Weekly (2008-07-22)
|
